Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALICAT feasibility study of extended low molecular weight heparin for cancer-associated thrombosis
2012-004117-14Phase 2Terminated
- Sponsor
- Cardiff University
- Start
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dalteparin, tinzaparin and enoxaparin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Cardiff University. Primary endpoint: Primary feasibility endpoint. Started Mar 2013; status: terminated.
02
Drugs
dalteparintinzaparinenoxaparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2012-004117-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004117-14.